Fuchs Endothelial Corneal Dystrophy (FECD) Market
Market Insights on Fuchs Endothelial Corneal Dystrophy (FECD) sales outlook, demand forecast & up-to-date key trends
Fuchs Endothelial Corneal Dystrophy (FECD) Market by Treatment, Diagnosis, End User & Region | Forecast 2023 to 2033
Fuchs Endothelial Corneal Dystrophy (FECD) Market Snapshot (2023 to 2033)
The global Fuchs endothelial corneal dystrophy (FECD) market garnered a market value of US$ 180 Billion in 2023 and is expected to accumulate a market value of US$ 370 Billion by registering a CAGR of 7.5% in the forecast period 2023-2033. The expanding worldwide aging population, as well as increased awareness of eye illnesses and corneal donation, is likely to boost the market. Furthermore, increased research interest in cellular treatment techniques is expected to generate significant potential for the Industry in the coming years.
The increased incidence of diabetes throughout the world will be a primary driver, resulting in an increase in the market's growth rate. According to the American Optometric Association, approximately 7 million people in the United States have undiagnosed diabetes, with 12,000 to 24,000 people losing their sight each year. Diabetic retinopathy is the leading cause of blindness in the United States today. Diabetic individuals must get a dilated eye exam once a year. By keeping a watch out for retinal anomalies, diabetic issues such as blindness and other consequences can be prevented.
In addition, the occurrence of different diseases such as cataracts, glaucoma, and age-related macular degeneration will drive market expansion. The growing healthcare spending, which aids in the improvement of its infrastructure, is a crucial element driving the growth rate of the market. Furthermore, numerous government organizations intend to improve healthcare infrastructure by boosting financing, which would have an impact on market dynamics.
|
Data Points |
Key Statistics |
|
Expected Market Value (2023) |
US$ 180 Billion |
|
Anticipated Forecast Value (2033) |
US$ 370 Billion |
|
Projected Growth Rate (2023 to 2033) |
7.5% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Fuchs Endothelial Corneal Dystrophy (FECD) Demand Analysis (2017 to 2022) Vs Market Outlook (2023 to 2033)
The global demand for Fuchs Endothelial Corneal Dystrophy (FECD) is projected to increase at a CAGR of 7.5% during the forecast period between 2023 and 2033, reaching a total of US$ 370 Billion in 2033, according to a report from Future Market Insights (FMI). From 2017 to 2021, sales witnessed significant growth, registering a CAGR of 6%.
The growing elderly population is expected to boost the market's growth rate. According to the World Ageing 2020 projection, there will be 727 million individuals aged 65 and over in 2020. This population is predicted to reach 1.5 billion by 2050. The proportion of the population aged 65 and older is expected to climb from 9.3% in 2020 to around 16.0% in 2050. The geriatric population is predicted to expand, and this group will require housing.
Furthermore, the growing number of government activities to raise awareness and change people's sedentary lifestyles will result in the rise of the market. Along with this, increased disposable income and expanding government-friendly programs would boost the market’s growth. The market's expansion is being propelled by an increase in the number of Research and Development activities. This would create advantageous prospects for the expansion of the market. Novel entrants are concentrating their efforts on developing new steroid-based formulations to treat dry eye syndrome (DES), which is also a key driving factor in the market.
Which are Some Prominent Drivers of Fuchs Endothelial Corneal Dystrophy (FECD) Market?
Expanding Worldwide Ageing Population to Improve Maintenance and Performance
The expanding worldwide ageing population, as well as increased awareness of eye illnesses and corneal donation, are likely to boost the market. Population growth and ageing are likely to drive up demand for eye care in the coming years. With the world's ageing population, the demand for corneal transplantation is expected to climb dramatically throughout the anticipated period.
Furthermore, researchers throughout the world are studying and developing novel technologies to guarantee the prompt treatment of individuals with Fuchs endothelial corneal dystrophy (FECD). Rising cellular therapy research activity is expected to generate significant prospects for the global market in the coming years.
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystWhich are the Trough Areas faced by the Fuchs Endothelial Corneal Dystrophy (FECD) Market?
Dangers Associated with Surgical Intervention to Slow Down the Market Growth
The dangers associated with surgical intervention, as well as a scarcity of donor grafts, may have an impact on market growth.
Region-Wise Insights
How will Fuchs Endothelial Corneal Dystrophy (FECD) Market Demand progress in the Asia Pacific?
Progressive Acceptance of Upgraded Technology to Widen Profit Margins
Asian nations are predicted to develop the quickest due to rising awareness, enhanced personal care and cleanliness, increased diagnostic rates, progressive acceptance of upgraded technology, rising disposable income, and burgeoning healthcare infrastructures. As per Future Market Insights, the Asia Pacific is expected to grow at a CAGR of 7% in the assessment period 2023 to 2033.
How attractive are Growth Prospects for Fuchs Endothelial Corneal Dystrophy (FECD) in North America?
Greater Healthcare Knowledge to Accelerate the Market
Because of greater healthcare knowledge, illness incidence, and a high rate of diagnosis, North America was found to have the highest share of the market.
In this multi-screen universe, individuals of all ages may be found. Computer or digital screen usage may result in less blinking, which may add to symptoms of Fuchs Endothelial Corneal Dystrophy (FECD), hence boosting the need for better and more effective Fuchs Endothelial Corneal Dystrophy (FECD) therapies, which is projected to stimulate growth in the North American region analyzed.
Furthermore, the region's expanding elderly population is driving market expansion since they are more susceptible to numerous ocular ailments such as Fuchs Endothelial Corneal Dystrophy (FECD). North America is expected to grow at a CAGR of 7.4% in the assessment period 2023 to 2033.
How is the European Fuchs Endothelial Corneal Dystrophy (FECD) Market Shaping?
Increased Research and Development to Drive the Market Growth
With increased research and development, Europe is providing the second-highest share of the Fuchs endothelial corneal dystrophy (FECD) market. Europe is the leading market for corneal transplants, and it will continue to grow in the near future due to the availability of various treatment options and prevention strategies, as well as the growing influence of organ donation programs and growing government focus on organ donation policies. Thus, owing to the aforementioned reasons, Europe is expected to grow at a CAGR of 7.3% in the assessment period 2023 to 2033.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Category-Wise Insights
Which is the Most Preferred End User in the Fuchs Endothelial Corneal Dystrophy (FECD)?
The Hospitals Segment to enhance Sales Prospects
The Fuchs Endothelial Corneal Dystrophy (FECD) market is divided into three segments based on end-users: hospitals, ASCS, and others. The hospital's segment accounts for the majority of the worldwide market.
Start-Ups for Fuchs Endothelial Corneal Dystrophy (FECD) Market
Key start-up players in the Fuchs Endothelial Corneal Dystrophy (FECD) are offering new and innovative product lines to consolidate their market presence, these aforementioned start-ups have left no stone unturned. Some specific instances of key Fuchs Endothelial Corneal Dystrophy (FECD) start-ups are as follows:
- Oculis is a clinical-stage biopharmaceutical business whose purpose is to create revolutionary topical medicines (eye drops) for ophthalmic illnesses in both the back and front of the eye, with the goal of improving patients' sight and lives globally. Our innovative formulation SNP technology represents a technological breakthrough in ocular medicine formulation, particularly for back-of-the-eye disorders presently treated with invasive approaches such as intraocular injections or implants.
- Nanodropper has created a patient-centered eye drops bottle adapter that reduces the capacity of already enormous eyedrops by more than 60%. This will assist to reduce the expense, waste, and potential negative effects of vision-saving procedures. Nanodropper's products and instructional content assist people in navigating challenges such as vision insurance, and eye doctor appointments, and efficiently deploying their resources. These programs support Nanodropper's aim of empowering people to regain control of their eye health.
- Azura Ophthalmics is developing the first ophthalmic keratolytic for the treatment of lid margin illnesses such as Meibomian gland dysfunction (MGD), Blepharitis, and Contact Lens Discomfort. Because Meibomian glands in the eyelids are comparable to hair follicles and sebaceous (oil-producing) glands in the skin1, we employ a combination of ophthalmologic and dermatologic approaches to create effective therapies for MGD and associated diseases.
Market Competition
The market for Fuchs Endothelial Corneal Dystrophy (FECD) is moderately competitive. With regard to market share, the industry is currently dominated by a few significant competitors. With the growing senior population and high illness incidence, a few new smaller competitors are projected to enter the industry in the next years.
Key players in the Fuchs endothelial corneal dystrophy market are Kowa Pharmaceuticals, Trefoil Therapeutics, Alcon, Emmecell, Santen, AJL Ophthalmic SA, Massachusetts Eye, and Ear, KeraMed, Inc, and Presbia Plc.
Recent Developments:
- In November 2022, Alcon, the worldwide eye care leader devoted to helping people see brilliantly, announced the completion of its purchase of Aerie Pharmaceuticals, Inc. With its expanding portfolio of commercial medicines and development pipeline, Alcon's footprint in the ophthalmic pharmaceutical field is strengthened by this deal.
Report Scope
|
Report Attribute |
Details |
|
Market Value in 2023 |
US$ 180 Billion |
|
Market Value in 2033 |
US$ 370 Billion |
|
Growth Rate |
CAGR of 7.5% from 2023 to 2033 |
|
Base Year for Estimation |
2022 |
|
Historical Data |
2018 to 2022 |
|
Forecast Period |
2023 to 2033 |
|
Quantitative Units |
Revenue in US Billion and CAGR from 2023-2033 |
|
Report Coverage |
Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
|
Segments Covered |
|
|
Regions Covered |
|
|
Key Countries Profiled |
|
|
Key Companies Profiled |
|
|
Customization |
Available Upon Request |
Key Segments Profiled in the Fuchs Endothelial Corneal Dystrophy (FECD) Market Industry Survey
By Treatment:
- Phototherapeutic Keratectomy
- Amniotic Membrane Transplants
- Anterior Stromal Puncture
- Conjunctival Flaps
By Diagnosis:
- Slit-lamp Examination
- Molecular Genetic Tests
- Pachymetry
By End User:
- Hospitals
- ASCs
- Others
By Region:
- North America
- Latin America
- Western Europe
- Eastern Europe
- Asia Pacific
- Middle East & Africa (MEA)
Frequently Asked Questions
What is the anticipated growth of the Fuchs Endothelial Corneal Dystrophy (FECD) market until 2033?
FMI projects the global Fuchs Endothelial Corneal Dystrophy (FECD) market to expand at a 7.5% value CAGR by 2033
What is the estimated market value of the Fuchs Endothelial Corneal Dystrophy (FECD) market expected in 2023?
The global Fuchs Endothelial Corneal Dystrophy (FECD) market is estimated at a market value of US$ 180 Billion
What is the estimated market value of Fuchs Endothelial Corneal Dystrophy (FECD) market expected in 2033?
The global Fuchs Endothelial Corneal Dystrophy (FECD) is expected to garner a market value of US$ 370 Billion
Which region is forecast to be the most lucrative Fuchs Endothelial Corneal Dystrophy (FECD) market growth?
As per Future Market Insights, the Asia Pacific is expected to grow at a CAGR of 7% in the assessment period 2023 to 2033.
Which are some prominent lucrative Fuchs Endothelial Corneal Dystrophy (FECD) manufacturers?
Key players in the Fuchs Endothelial Corneal Dystrophy (FECD) market are Kowa Pharmaceuticals, Trefoil Therapeutics, Alcon, Emmecell, Santen, AJL Ophthalmic SA, Massachusetts Eye, and Ear, KeraMed, Inc and Presbia Plc.
What is the expected market share of North America in the lucrative Fuchs Endothelial Corneal Dystrophy (FECD) market?
North America is expected to grow at a CAGR of 7.4% in the assessment period 2023 to 2033.
What is the expected market share of Europe for lucrative Fuchs Endothelial Corneal Dystrophy (FECD)?
Europe is expected to grow at a CAGR of 7.3% in the assessment period 2023 to 2033.
Which type of vehicle is expected to hold the largest market share for lucrative Fuchs Endothelial Corneal Dystrophy (FECD) in the forecast period 2023 to 2033?
The hospitals segment is expected to hold the largest market share for lucrative Fuchs Endothelial Corneal Dystrophy (FECD) in the forecast period 2023-2033.
Table of Content
1. Executive Summary | Fuchs Endothelial Corneal Dystrophy (FECD) Market 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022 4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) Analysis By Treatment, 2018 to 2022 5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Treatment, 2023 to 2033 5.3.1. Phototherapeutic Keratectomy 5.3.2. AMillioniotic Membrane Transplants 5.3.3. Anterior Stromal Puncture 5.3.4. Conjunctival Flaps 5.4. Y-o-Y Growth Trend Analysis By Treatment, 2018 to 2022 5.5. Absolute $ Opportunity Analysis By Treatment, 2023 to 2033 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Diagnosis 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) Analysis By Diagnosis, 2018 to 2022 6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Diagnosis, 2023 to 2033 6.3.1. Slit-lamp Examination 6.3.2. Molecular Genetic Tests 6.3.3. Pachymetry 6.4. Y-o-Y Growth Trend Analysis By Diagnosis, 2018 to 2022 6.5. Absolute $ Opportunity Analysis By Diagnosis, 2023 to 2033 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End Users 7.1. Introduction / Key Findings 7.2. Historical Market Size Value (US$ Million) Analysis By End Users, 2018 to 2022 7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End Users , 2023 to 2033 7.3.1. Hospitals 7.3.2. ASCs 7.3.3. Others 7.4. Y-o-Y Growth Trend Analysis By End Users, 2018 to 2022 7.5. Absolute $ Opportunity Analysis By End Users, 2023 to 2033 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 8.1. Introduction 8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022 8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033 8.3.1. North America 8.3.2. Latin America 8.3.3. Western Europe 8.3.4. Eastern Europe 8.3.5. Asia-Pacific 8.3.6. Middle East & Africa (MEA) 8.4. Market Attractiveness Analysis By Region 9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 9.2.1. By Country 9.2.1.1. The US 9.2.1.2. Canada 9.2.2. By Treatment 9.2.3. By Diagnosis 9.2.4. By End Users 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Treatment 9.3.3. By Diagnosis 9.3.4. By End Users 9.4. Key Takeaways 10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 10.2.1. By Country 10.2.1.1. Brazil 10.2.1.2. Mexico 10.2.1.3. Rest of Latin America 10.2.2. By Treatment 10.2.3. By Diagnosis 10.2.4. By End Users 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Treatment 10.3.3. By Diagnosis 10.3.4. By End Users 10.4. Key Takeaways 11. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 11.2.1. By Country 11.2.1.1. Benelux 11.2.1.2. France 11.2.1.3. Germany 11.2.1.4. Italy 11.2.1.5. Nordic 11.2.1.6. Spain 11.2.1.7. The UK 11.2.1.8. Rest of Western Europe 11.2.2. By Treatment 11.2.3. By Diagnosis 11.2.4. By End Users 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Treatment 11.3.3. By Diagnosis 11.3.4. By End Users 11.4. Key Takeaways 12. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 12.2.1. By Country 12.2.1.1. Poland 12.2.1.2. Russia 12.2.1.3. Rest of Eastern Europe 12.2.2. By Treatment 12.2.3. By Diagnosis 12.2.4. By End Users 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Treatment 12.3.3. By Diagnosis 12.3.4. By End Users 12.4. Key Takeaways 13. APAC Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 13.2.1. By Country 13.2.1.1. India 13.2.1.2. Malaysia 13.2.1.3. Singapore 13.2.1.4. Thailand 13.2.1.5. Australia 13.2.1.6. New Zealand 13.2.1.7. Rest of APAC 13.2.2. By Treatment 13.2.3. By Diagnosis 13.2.4. By End Users 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Treatment 13.3.3. By Diagnosis 13.3.4. By End Users 13.4. Key Takeaways 14. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 14.2.1. By Country 14.2.1.1. GCC Countries 14.2.1.2. South Africa 14.2.1.3. Israel 14.2.1.4. Rest of MEA 14.2.2. By Treatment 14.2.3. By Diagnosis 14.2.4. By End Users 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Treatment 14.3.3. By Diagnosis 14.3.4. By End Users 14.4. Key Takeaways 15. Key Countries Market Analysis 15.1. The US 15.1.1. Pricing Analysis 15.1.2. Market Share Analysis, 2022 15.1.2.1. By Treatment 15.1.2.2. By Diagnosis 15.1.2.3. By End Users 15.2. Canada 15.2.1. Pricing Analysis 15.2.2. Market Share Analysis, 2022 15.2.2.1. By Treatment 15.2.2.2. By Diagnosis 15.2.2.3. By End Users 15.3. Brazil 15.3.1. Pricing Analysis 15.3.2. Market Share Analysis, 2022 15.3.2.1. By Treatment 15.3.2.2. By Diagnosis 15.3.2.3. By End Users 15.4. Mexico 15.4.1. Pricing Analysis 15.4.2. Market Share Analysis, 2022 15.4.2.1. By Treatment 15.4.2.2. By Diagnosis 15.4.2.3. By End Users 15.5. Benelux 15.5.1. Pricing Analysis 15.5.2. Market Share Analysis, 2022 15.5.2.1. By Treatment 15.5.2.2. By Diagnosis 15.5.2.3. By End Users 15.6. France 15.6.1. Pricing Analysis 15.6.2. Market Share Analysis, 2022 15.6.2.1. By Treatment 15.6.2.2. By Diagnosis 15.6.2.3. By End Users 15.7. Germany 15.7.1. Pricing Analysis 15.7.2. Market Share Analysis, 2022 15.7.2.1. By Treatment 15.7.2.2. By Diagnosis 15.7.2.3. By End Users 15.8. Italy 15.8.1. Pricing Analysis 15.8.2. Market Share Analysis, 2022 15.8.2.1. By Treatment 15.8.2.2. By Diagnosis 15.8.2.3. By End Users 15.9. Nordic 15.9.1. Pricing Analysis 15.9.2. Market Share Analysis, 2022 15.9.2.1. By Treatment 15.9.2.2. By Diagnosis 15.9.2.3. By End Users 15.10. Spain 15.10.1. Pricing Analysis 15.10.2. Market Share Analysis, 2022 15.10.2.1. By Treatment 15.10.2.2. By Diagnosis 15.10.2.3. By End Users 15.11. The UK 15.11.1. Pricing Analysis 15.11.2. Market Share Analysis, 2022 15.11.2.1. By Treatment 15.11.2.2. By Diagnosis 15.11.2.3. By End Users 15.12. Poland 15.12.1. Pricing Analysis 15.12.2. Market Share Analysis, 2022 15.12.2.1. By Treatment 15.12.2.2. By Diagnosis 15.12.2.3. By End Users 15.13. Russia 15.13.1. Pricing Analysis 15.13.2. Market Share Analysis, 2022 15.13.2.1. By Treatment 15.13.2.2. By Diagnosis 15.13.2.3. By End Users 15.14. India 15.14.1. Pricing Analysis 15.14.2. Market Share Analysis, 2022 15.14.2.1. By Treatment 15.14.2.2. By Diagnosis 15.14.2.3. By End Users 15.15. Malaysia 15.15.1. Pricing Analysis 15.15.2. Market Share Analysis, 2022 15.15.2.1. By Treatment 15.15.2.2. By Diagnosis 15.15.2.3. By End Users 15.16. Singapore 15.16.1. Pricing Analysis 15.16.2. Market Share Analysis, 2022 15.16.2.1. By Treatment 15.16.2.2. By Diagnosis 15.16.2.3. By End Users 15.17. Thailand 15.17.1. Pricing Analysis 15.17.2. Market Share Analysis, 2022 15.17.2.1. By Treatment 15.17.2.2. By Diagnosis 15.17.2.3. By End Users 15.18. Australia 15.18.1. Pricing Analysis 15.18.2. Market Share Analysis, 2022 15.18.2.1. By Treatment 15.18.2.2. By Diagnosis 15.18.2.3. By End Users 15.19. New Zealand 15.19.1. Pricing Analysis 15.19.2. Market Share Analysis, 2022 15.19.2.1. By Treatment 15.19.2.2. By Diagnosis 15.19.2.3. By End Users 15.20. GCC Countries 15.20.1. Pricing Analysis 15.20.2. Market Share Analysis, 2022 15.20.2.1. By Treatment 15.20.2.2. By Diagnosis 15.20.2.3. By End Users 15.21. South Africa 15.21.1. Pricing Analysis 15.21.2. Market Share Analysis, 2022 15.21.2.1. By Treatment 15.21.2.2. By Diagnosis 15.21.2.3. By End Users 15.22. Israel 15.22.1. Pricing Analysis 15.22.2. Market Share Analysis, 2022 15.22.2.1. By Treatment 15.22.2.2. By Diagnosis 15.22.2.3. By End Users 16. Market Structure Analysis 16.1. Competition Dashboard 16.2. Competition Benchmarking 16.3. Market Share Analysis of Top Players 16.3.1. By Regional 16.3.2. By Treatment 16.3.3. By Diagnosis 16.3.4. By End Users 17. Competition Analysis 17.1. Competition Deep Dive 17.1.1. Kowa Pharmaceuticals 17.1.1.1. Overview 17.1.1.2. Product Portfolio 17.1.1.3. Profitability by Market Segments 17.1.1.4. Sales Footprint 17.1.1.5. Strategy Overview 17.1.1.5.1. Marketing Strategy 17.1.2. Trefoil Therapeutics 17.1.2.1. Overview 17.1.2.2. Product Portfolio 17.1.2.3. Profitability by Market Segments 17.1.2.4. Sales Footprint 17.1.2.5. Strategy Overview 17.1.2.5.1. Marketing Strategy 17.1.3. Alcon 17.1.3.1. Overview 17.1.3.2. Product Portfolio 17.1.3.3. Profitability by Market Segments 17.1.3.4. Sales Footprint 17.1.3.5. Strategy Overview 17.1.3.5.1. Marketing Strategy 17.1.4. Emmecell 17.1.4.1. Overview 17.1.4.2. Product Portfolio 17.1.4.3. Profitability by Market Segments 17.1.4.4. Sales Footprint 17.1.4.5. Strategy Overview 17.1.4.5.1. Marketing Strategy 17.1.5. Santen 17.1.5.1. Overview 17.1.5.2. Product Portfolio 17.1.5.3. Profitability by Market Segments 17.1.5.4. Sales Footprint 17.1.5.5. Strategy Overview 17.1.5.5.1. Marketing Strategy 17.1.6. AJL Ophthalmic SA 17.1.6.1. Overview 17.1.6.2. Product Portfolio 17.1.6.3. Profitability by Market Segments 17.1.6.4. Sales Footprint 17.1.6.5. Strategy Overview 17.1.6.5.1. Marketing Strategy 17.1.7. Massachusetts Eye and Ear 17.1.7.1. Overview 17.1.7.2. Product Portfolio 17.1.7.3. Profitability by Market Segments 17.1.7.4. Sales Footprint 17.1.7.5. Strategy Overview 17.1.7.5.1. Marketing Strategy 17.1.8. Alcon, Inc. 17.1.8.1. Overview 17.1.8.2. Product Portfolio 17.1.8.3. Profitability by Market Segments 17.1.8.4. Sales Footprint 17.1.8.5. Strategy Overview 17.1.8.5.1. Marketing Strategy 17.1.9. KeraMed, Inc. 17.1.9.1. Overview 17.1.9.2. Product Portfolio 17.1.9.3. Profitability by Market Segments 17.1.9.4. Sales Footprint 17.1.9.5. Strategy Overview 17.1.9.5.1. Marketing Strategy 17.1.10. Presbia Plc 17.1.10.1. Overview 17.1.10.2. Product Portfolio 17.1.10.3. Profitability by Market Segments 17.1.10.4. Sales Footprint 17.1.10.5. Strategy Overview 17.1.10.5.1. Marketing Strategy 18. Assumptions & Acronyms Used 19. Research Methodology
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
List of Tables
Table 1: Global Market Value (US$ Million) Forecast by Region, 2018 to 2033 Table 2: Global Market Value (US$ Million) Forecast by Treatment, 2018 to 2033 Table 3: Global Market Value (US$ Million) Forecast by Diagnosis, 2018 to 2033 Table 4: Global Market Value (US$ Million) Forecast by End Users, 2018 to 2033 Table 5: North America Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 6: North America Market Value (US$ Million) Forecast by Treatment, 2018 to 2033 Table 7: North America Market Value (US$ Million) Forecast by Diagnosis, 2018 to 2033 Table 8: North America Market Value (US$ Million) Forecast by End Users, 2018 to 2033 Table 9: Latin America Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 10: Latin America Market Value (US$ Million) Forecast by Treatment, 2018 to 2033 Table 11: Latin America Market Value (US$ Million) Forecast by Diagnosis, 2018 to 2033 Table 12: Latin America Market Value (US$ Million) Forecast by End Users, 2018 to 2033 Table 13: Western Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 14: Western Europe Market Value (US$ Million) Forecast by Treatment, 2018 to 2033 Table 15: Western Europe Market Value (US$ Million) Forecast by Diagnosis, 2018 to 2033 Table 16: Western Europe Market Value (US$ Million) Forecast by End Users, 2018 to 2033 Table 17: Eastern Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 18: Eastern Europe Market Value (US$ Million) Forecast by Treatment, 2018 to 2033 Table 19: Eastern Europe Market Value (US$ Million) Forecast by Diagnosis, 2018 to 2033 Table 20: Eastern Europe Market Value (US$ Million) Forecast by End Users, 2018 to 2033 Table 21: APAC Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 22: APAC Market Value (US$ Million) Forecast by Treatment, 2018 to 2033 Table 23: APAC Market Value (US$ Million) Forecast by Diagnosis, 2018 to 2033 Table 24: APAC Market Value (US$ Million) Forecast by End Users, 2018 to 2033 Table 25: MEA Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 26: MEA Market Value (US$ Million) Forecast by Treatment, 2018 to 2033 Table 27: MEA Market Value (US$ Million) Forecast by Diagnosis, 2018 to 2033 Table 28: MEA Market Value (US$ Million) Forecast by End Users, 2018 to 2033
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystList of Charts
Figure 1: Global Market Value (US$ Million) by Treatment, 2023 to 2033 Figure 2: Global Market Value (US$ Million) by Diagnosis, 2023 to 2033 Figure 3: Global Market Value (US$ Million) by End Users, 2023 to 2033 Figure 4: Global Market Value (US$ Million) by Region, 2023 to 2033 Figure 5: Global Market Value (US$ Million) Analysis by Region, 2018 to 2033 Figure 6: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033 Figure 7: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033 Figure 8: Global Market Value (US$ Million) Analysis by Treatment, 2018 to 2033 Figure 9: Global Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033 Figure 10: Global Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033 Figure 11: Global Market Value (US$ Million) Analysis by Diagnosis, 2018 to 2033 Figure 12: Global Market Value Share (%) and BPS Analysis by Diagnosis, 2023 to 2033 Figure 13: Global Market Y-o-Y Growth (%) Projections by Diagnosis, 2023 to 2033 Figure 14: Global Market Value (US$ Million) Analysis by End Users, 2018 to 2033 Figure 15: Global Market Value Share (%) and BPS Analysis by End Users, 2023 to 2033 Figure 16: Global Market Y-o-Y Growth (%) Projections by End Users, 2023 to 2033 Figure 17: Global Market Attractiveness by Treatment, 2023 to 2033 Figure 18: Global Market Attractiveness by Diagnosis, 2023 to 2033 Figure 19: Global Market Attractiveness by End Users, 2023 to 2033 Figure 20: Global Market Attractiveness by Region, 2023 to 2033 Figure 21: North America Market Value (US$ Million) by Treatment, 2023 to 2033 Figure 22: North America Market Value (US$ Million) by Diagnosis, 2023 to 2033 Figure 23: North America Market Value (US$ Million) by End Users, 2023 to 2033 Figure 24: North America Market Value (US$ Million) by Country, 2023 to 2033 Figure 25: North America Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 26: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 27: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 28: North America Market Value (US$ Million) Analysis by Treatment, 2018 to 2033 Figure 29: North America Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033 Figure 30: North America Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033 Figure 31: North America Market Value (US$ Million) Analysis by Diagnosis, 2018 to 2033 Figure 32: North America Market Value Share (%) and BPS Analysis by Diagnosis, 2023 to 2033 Figure 33: North America Market Y-o-Y Growth (%) Projections by Diagnosis, 2023 to 2033 Figure 34: North America Market Value (US$ Million) Analysis by End Users, 2018 to 2033 Figure 35: North America Market Value Share (%) and BPS Analysis by End Users, 2023 to 2033 Figure 36: North America Market Y-o-Y Growth (%) Projections by End Users, 2023 to 2033 Figure 37: North America Market Attractiveness by Treatment, 2023 to 2033 Figure 38: North America Market Attractiveness by Diagnosis, 2023 to 2033 Figure 39: North America Market Attractiveness by End Users, 2023 to 2033 Figure 40: North America Market Attractiveness by Country, 2023 to 2033 Figure 41: Latin America Market Value (US$ Million) by Treatment, 2023 to 2033 Figure 42: Latin America Market Value (US$ Million) by Diagnosis, 2023 to 2033 Figure 43: Latin America Market Value (US$ Million) by End Users, 2023 to 2033 Figure 44: Latin America Market Value (US$ Million) by Country, 2023 to 2033 Figure 45: Latin America Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 46: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 47: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 48: Latin America Market Value (US$ Million) Analysis by Treatment, 2018 to 2033 Figure 49: Latin America Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033 Figure 50: Latin America Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033 Figure 51: Latin America Market Value (US$ Million) Analysis by Diagnosis, 2018 to 2033 Figure 52: Latin America Market Value Share (%) and BPS Analysis by Diagnosis, 2023 to 2033 Figure 53: Latin America Market Y-o-Y Growth (%) Projections by Diagnosis, 2023 to 2033 Figure 54: Latin America Market Value (US$ Million) Analysis by End Users, 2018 to 2033 Figure 55: Latin America Market Value Share (%) and BPS Analysis by End Users, 2023 to 2033 Figure 56: Latin America Market Y-o-Y Growth (%) Projections by End Users, 2023 to 2033 Figure 57: Latin America Market Attractiveness by Treatment, 2023 to 2033 Figure 58: Latin America Market Attractiveness by Diagnosis, 2023 to 2033 Figure 59: Latin America Market Attractiveness by End Users, 2023 to 2033 Figure 60: Latin America Market Attractiveness by Country, 2023 to 2033 Figure 61: Western Europe Market Value (US$ Million) by Treatment, 2023 to 2033 Figure 62: Western Europe Market Value (US$ Million) by Diagnosis, 2023 to 2033 Figure 63: Western Europe Market Value (US$ Million) by End Users, 2023 to 2033 Figure 64: Western Europe Market Value (US$ Million) by Country, 2023 to 2033 Figure 65: Western Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 66: Western Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 67: Western Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 68: Western Europe Market Value (US$ Million) Analysis by Treatment, 2018 to 2033 Figure 69: Western Europe Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033 Figure 70: Western Europe Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033 Figure 71: Western Europe Market Value (US$ Million) Analysis by Diagnosis, 2018 to 2033 Figure 72: Western Europe Market Value Share (%) and BPS Analysis by Diagnosis, 2023 to 2033 Figure 73: Western Europe Market Y-o-Y Growth (%) Projections by Diagnosis, 2023 to 2033 Figure 74: Western Europe Market Value (US$ Million) Analysis by End Users, 2018 to 2033 Figure 75: Western Europe Market Value Share (%) and BPS Analysis by End Users, 2023 to 2033 Figure 76: Western Europe Market Y-o-Y Growth (%) Projections by End Users, 2023 to 2033 Figure 77: Western Europe Market Attractiveness by Treatment, 2023 to 2033 Figure 78: Western Europe Market Attractiveness by Diagnosis, 2023 to 2033 Figure 79: Western Europe Market Attractiveness by End Users, 2023 to 2033 Figure 80: Western Europe Market Attractiveness by Country, 2023 to 2033 Figure 81: Eastern Europe Market Value (US$ Million) by Treatment, 2023 to 2033 Figure 82: Eastern Europe Market Value (US$ Million) by Diagnosis, 2023 to 2033 Figure 83: Eastern Europe Market Value (US$ Million) by End Users, 2023 to 2033 Figure 84: Eastern Europe Market Value (US$ Million) by Country, 2023 to 2033 Figure 85: Eastern Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 86: Eastern Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 87: Eastern Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 88: Eastern Europe Market Value (US$ Million) Analysis by Treatment, 2018 to 2033 Figure 89: Eastern Europe Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033 Figure 90: Eastern Europe Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033 Figure 91: Eastern Europe Market Value (US$ Million) Analysis by Diagnosis, 2018 to 2033 Figure 92: Eastern Europe Market Value Share (%) and BPS Analysis by Diagnosis, 2023 to 2033 Figure 93: Eastern Europe Market Y-o-Y Growth (%) Projections by Diagnosis, 2023 to 2033 Figure 94: Eastern Europe Market Value (US$ Million) Analysis by End Users, 2018 to 2033 Figure 95: Eastern Europe Market Value Share (%) and BPS Analysis by End Users, 2023 to 2033 Figure 96: Eastern Europe Market Y-o-Y Growth (%) Projections by End Users, 2023 to 2033 Figure 97: Eastern Europe Market Attractiveness by Treatment, 2023 to 2033 Figure 98: Eastern Europe Market Attractiveness by Diagnosis, 2023 to 2033 Figure 99: Eastern Europe Market Attractiveness by End Users, 2023 to 2033 Figure 100: Eastern Europe Market Attractiveness by Country, 2023 to 2033 Figure 101: APAC Market Value (US$ Million) by Treatment, 2023 to 2033 Figure 102: APAC Market Value (US$ Million) by Diagnosis, 2023 to 2033 Figure 103: APAC Market Value (US$ Million) by End Users, 2023 to 2033 Figure 104: APAC Market Value (US$ Million) by Country, 2023 to 2033 Figure 105: APAC Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 106: APAC Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 107: APAC Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 108: APAC Market Value (US$ Million) Analysis by Treatment, 2018 to 2033 Figure 109: APAC Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033 Figure 110: APAC Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033 Figure 111: APAC Market Value (US$ Million) Analysis by Diagnosis, 2018 to 2033 Figure 112: APAC Market Value Share (%) and BPS Analysis by Diagnosis, 2023 to 2033 Figure 113: APAC Market Y-o-Y Growth (%) Projections by Diagnosis, 2023 to 2033 Figure 114: APAC Market Value (US$ Million) Analysis by End Users, 2018 to 2033 Figure 115: APAC Market Value Share (%) and BPS Analysis by End Users, 2023 to 2033 Figure 116: APAC Market Y-o-Y Growth (%) Projections by End Users, 2023 to 2033 Figure 117: APAC Market Attractiveness by Treatment, 2023 to 2033 Figure 118: APAC Market Attractiveness by Diagnosis, 2023 to 2033 Figure 119: APAC Market Attractiveness by End Users, 2023 to 2033 Figure 120: APAC Market Attractiveness by Country, 2023 to 2033 Figure 121: MEA Market Value (US$ Million) by Treatment, 2023 to 2033 Figure 122: MEA Market Value (US$ Million) by Diagnosis, 2023 to 2033 Figure 123: MEA Market Value (US$ Million) by End Users, 2023 to 2033 Figure 124: MEA Market Value (US$ Million) by Country, 2023 to 2033 Figure 125: MEA Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 126: MEA Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 127: MEA Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 128: MEA Market Value (US$ Million) Analysis by Treatment, 2018 to 2033 Figure 129: MEA Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033 Figure 130: MEA Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033 Figure 131: MEA Market Value (US$ Million) Analysis by Diagnosis, 2018 to 2033 Figure 132: MEA Market Value Share (%) and BPS Analysis by Diagnosis, 2023 to 2033 Figure 133: MEA Market Y-o-Y Growth (%) Projections by Diagnosis, 2023 to 2033 Figure 134: MEA Market Value (US$ Million) Analysis by End Users, 2018 to 2033 Figure 135: MEA Market Value Share (%) and BPS Analysis by End Users, 2023 to 2033 Figure 136: MEA Market Y-o-Y Growth (%) Projections by End Users, 2023 to 2033 Figure 137: MEA Market Attractiveness by Treatment, 2023 to 2033 Figure 138: MEA Market Attractiveness by Diagnosis, 2023 to 2033 Figure 139: MEA Market Attractiveness by End Users, 2023 to 2033 Figure 140: MEA Market Attractiveness by Country, 2023 to 2033
Recommendations
Explore Healthcare Insights
View Reports
